Results 31 to 40 of about 961,893 (364)
Addendum: Action potential propagation and block in a model of atrial tissue with myocyte-fibroblast coupling [PDF]
, 2021 The analytical theory of our earlier study (Mortensen et al. (2021), Mathematical Medicine and Biology, 38(1), pp. 106-131) is extended to address the outstanding cases of fibroblast barrier distribution and myocyte strait distribution. In particular, closed-form approximations to the resting membrane potential and to the critical parameter values for ...
arxiv +1 more source
Fibroblast growth factor 23 and symmetric dimethylarginine concentrations in geriatric cats [PDF]
Journal of Veterinary Internal Medicine, 2019 Background Fibroblast growth factor 23 (FGF23) is a phosphaturic hormone that is increased in azotemic cats with chronic kidney disease (CKD) and predictive of the onset of azotemia in older cats.
Bijsmans, E S +5 more
core +2 more sources
MicroRNA-297a regulates vascular calcification by targeting fibroblast growth factor 23 [PDF]
Iranian Journal of Basic Medical Sciences, 2016 Objective(s): Vascular calcification is one the major characteristics in patients with various types of chronic inflammatory disorders. MiRNAs have been shown to be involved in many normal biological functions as well as diseases; however, their role in ...
Shouhua Zheng +6 more
doaj +1 more source
Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis [PDF]
, 2019 Background: Etelcalcetide is an intravenous calcimimetic approved for treatment of secondary hyperparathyroidism (sHPT) in patients receiving hemodialysis. Besides lowering parathyroid hormone (PTH), etelcalcetide also significantly reduces fibroblast
Block, Geoffrey A. +9 more
core +1 more source
Update on fibroblast growth factor 23 in chronic kidney disease [PDF]
, 2012 Chronic kidney disease (CKD) is a public health epidemic that affects millions of people worldwide. Presence of CKD predisposes individuals to high risks of end-stage renal disease (ESRD), cardiovascular disease, and premature death. Disordered phosphate
Wolf, Myles
core +1 more source
How Fibroblast Growth Factor 23 Works [PDF]
Journal of the American Society of Nephrology, 2007 There is a discontinuum of hereditary and acquired disorders of phosphate homeostasis that are caused by either high or low circulating levels of the novel phosphaturic hormone fibroblastic growth factor 23 (FGF23). Disorders that are caused by high circulating levels of FGF23 are characterized by hypophosphatemia, decreased production of 1,25 ...
Shiguang Liu, L. Darryl Quarles
openaire +3 more sources
Comparison of particle-size analyzing laboratory methods [PDF]
, 2015 Patients with chronic renal failure are known to have renal osteodystrophy (bone disease) and increased calcification of vessels. A new marker of bone disease, sclerostin, the two pro-inflammatory cytokines tumour necrosis factor-alpha (TNF-alpha) and ...
Barta, Károly +6 more
core +1 more source
Strategies to lower fibroblast growth factor 23 bioactivity [PDF]
Nephrology Dialysis Transplantation, 2021 Abstract Fibroblast growth factor 23 (FGF23) is a circulating hormone derived from the bone whose release is controlled by many factors and exerts a multitude of systemic actions. There are congenital and acquired disorders of increased and decreased FGF23 levels.
Orson W. Moe, Devin Verbueken
openaire +2 more sources
Fibroblast growth factor 23: the making of a hormone [PDF]
Kidney International, 2006 Fibroblast growth factor 23 (FGF23) modulates serum phosphate and 1alpha,25-dihydroxyvitamin D3 levels. FGF23 expression is in turn regulated by 1alpha,25-dihydroxyvitamin D3 and dietary phosphate load, and is strikingly elevated during renal progression.
openaire +3 more sources
Multiple faces of fibroblast growth factor-23 [PDF]
Current Opinion in Nephrology and Hypertension, 2016 This review examines the role of fibroblast growth factor-23 (FGF-23) in mineral metabolism, innate immunity and adverse cardiovascular outcomes.FGF-23, produced by osteocytes in bone, activates FGFR/α-Klotho (α-Kl) complexes in the kidney. The resulting bone-kidney axis coordinates renal phosphate reabsorption with bone mineralization, and creates a ...
Leigh Darryl Quarles, Xiaobin Han
openaire +3 more sources